4-羟基雌三醇 | 60021-32-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 4-羟基雌三醇
• 英文名称: 4-hydroxyestriol
• 英文别名: (8R,9S,13S,14S,16R,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,4,16,17-tetrol
• CAS: 60021-32-1
• 化学式: C₁₈H₂₄O₄
• 分子量: 304.386
• InChiKey: KKXSCWWODCABHQ-OZPBLJIJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  80.9
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  雌三醇 16,17-二乙酸酯 在 硝酸 、 sodium nitrite 作用下， 生成 4-羟基雌三醇
  参考文献：
  名称：

  Convenient large scale preparation of catechol estrogens

  摘要：

  2-Hydroxyestrone, 2-hydroxyestradiol-17beta, 2-hydroxy-17alpha-ethynylestradiol, 2-hydroxyestriol, 4-hydroxyestrone, 4-hydroxyestradiol-17beta, 4-hydroxy-17alpha-ethynylestradiol and 4-hydroxyestriol are prepared on a preparative scale from the corresponding aminophenols using a new inverse oxidation procedure. By the synthesis described both the 2- and 4-hydroxylated estrogens are available in high yields.

  DOI：

  10.1016/0039-128x(76)90010-6

文献信息

• Syntheses of 4-hydroxyestriol monoglucuronides and monosulfates.
  作者：KAZUTAKE SHIMADA、FUMING XIE、TOSHIO NAMBARA

  DOI：10.1248/cpb.34.179

  日期：——

  The A-ring monoglucuronides and monosulfates of 4-hydroxyesteriol were synthesized from 4-hydroxyestriol 16, 17-diacetate by means of the Koenigs-Knorr reaction with methyl α-acetobromoglucuronate and sulfation with sulfur trioxide-pyridine complex, respectively. The conjugated positions of these compounds were unequivocally elucidated by leading the products to guaiacol estrogens. The D-ring monoglucuronides and monosulfates of 4-hydroxyestriol were also obtained from 4-hydroxyestriol 3, 4-dibenzyl ether by glucuronidation and sulfation followed by hydrogenolysis, respectively. The conjugated positions were established on the basis of spectral data of derivatives. The preparation of 4-hydroxyestradiol 17-conjugates is also described.

  通过与α-乙酰溴葡萄糖醛酸甲酯的柯尼希斯-克诺尔反应和与三氧化硫-吡啶络合物的硫化反应，分别从 4-羟基雌三醇 16，17-二乙酸酯合成了 4-羟基雌三醇的 A 环单葡糖醛酸酯和单硫酸盐。通过将产物引向愈创木酚雌激素，明确地阐明了这些化合物的共轭位置。通过葡萄糖醛酸化和硫酸化，再通过氢解，还分别从 4-羟基雌三醇 3，4-二苄醚中得到了 4-羟基雌三醇的 D 环单葡萄糖醛酸化物和单硫酸盐。根据衍生物的光谱数据确定了共轭位置。此外，还介绍了 4-羟基雌二醇 17-共轭物的制备方法。
• Prevention of mammary carcinoma
  申请人：The Board of Regents of the University of Nebraska

  公开号：EP0240717A2

  公开（公告）日：1987-10-14

  To reduce the risk of breast cancer, a drug is periodically administered to young mammals before pregnancy in doses of about 1 microgram to 50 micrograms per killogram of body weight. The drug: (1) competes with and displaces estradiol 17 beta from the mammary gland cells in an effective manner to prevent the possible formation of DNA-damaging epoxide estradiol metabolites; (2) binds to breast tissue to a greater extent than estradiol 17 beta; (3) induces terminal nonlacta- tion differentiation of the mammary gland; (4) is nontoxic and noncarcinogenic; and (5) preferably does not have anti-ovulatory activity. The drug is selected from a group of drugs including: (1)4-OH estradiol; (2) d-equilenin; and (3) 17 alpha ethynyl estriol.

  为了降低罹患乳腺癌的风险，在怀孕前定期给幼年哺乳动物服用一种药物，剂量约为每千克体重 1 微克至 50 微克。该药物：(1) 与雌二醇 17 beta 竞争并以有效的方式从乳腺细胞中置换出来，以防止可能形成的破坏 DNA 的环氧雌二醇代谢物；(2) 与乳腺组织的结合程度高于雌二醇 17 beta；(3) 诱导乳腺的末端非乳腺分化；(4) 无毒且不致癌；(5) 最好不具有抗排卵活性。该药物选自一组药物，包括：(1)4-OH 雌二醇；(2)d-喹诺酮；(3)17α 乙炔基雌三醇。
• REMEDY FOR HORMONE-DEPENDENT CANCER
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1568381A1

  公开（公告）日：2005-08-31

  A therapeutic agent for a hormone-dependent cancer, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy, which may be administered together or separately at an interval, is provided. A method for treating a hormone-dependent cancer, which comprises administering (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy together or separately at an interval, is also provided. A steroid-sulfatase inhibitor which is used in combination with an agent for hormone therapy and/or an agent for chemotherapy, and which is administered together therewith or separately therefrom at an interval, is also provided. A kit for treating a hormone-dependent cancer, which comprises a first component comprising (a) a steroid-sulfatase inhibitor and a second component comprising (b) an agent for hormone therapy and/or an agent for chemotherapy, is also provided. A pharmaceutical composition, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy, is also provided. Further, use of (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy for the manufacture of a therapeutic agent for a hormone-dependent cancer is provided.

  本发明提供了一种激素依赖性癌症的治疗剂，它包括(a)类固醇硫酸酯酶抑制剂和(b)激素治疗剂和/或化疗剂，这两种药物可以一起给药，也可以间隔一段时间分别给药。还提供了一种治疗激素依赖性癌症的方法，该方法包括(a)类固醇-硫酸酯酶抑制剂和(b)激素治疗制剂和/或化疗制剂，它们可以一起给药，也可以间隔一段时间分别给药。还提供了一种类固醇硫酸酯酶抑制剂，该抑制剂与激素治疗剂和/或化疗剂联合使用，并在一定间隔时间内一起或分开给药。还提供了一种用于治疗激素依赖性癌症的试剂盒，它包括由(a)类固醇硫酸酯酶抑制剂组成的第一组分和由(b)激素治疗剂和/或化疗剂组成的第二组分。还提供了一种药物组合物，它包含(a)类固醇硫酸酯酶抑制剂和(b)激素治疗剂和/或化疗剂。此外，还提供了使用(a)类固醇硫酸酯酶抑制剂和(b)激素治疗剂和/或化疗剂制造激素依赖性癌症治疗剂的方法。
• Remedy for hormone-dependent cancer
  申请人：Shiotsu Yukimasa

  公开号：US20060035875A1

  公开（公告）日：2006-02-16

  A therapeutic agent for a hormone-dependent cancer, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy, which may be administered together or separately at an interval, is provided. A method for treating a hormone-dependent cancer, which comprises administering (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy together or separately at an interval, is also provided. A steroid-sulfatase inhibitor which is used in combination with an agent for hormone therapy and/or an agent for chemotherapy, and which is administered together therewith or separately therefrom at an interval, is also provided. A kit for treating a hormone-dependent cancer, which comprises a first component comprising (a) a steroid-sulfatase inhibitor and a second component comprising (b) an agent for hormone therapy and/or an agent for chemotherapy, is also provided. A pharmaceutical composition, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy, is also provided. Further, use of (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy for the manufacture of a therapeutic agent for a hormone-dependent cancer is provided.
• Steroid sulphatase inhibitors
  申请人：Reed John Michael

  公开号：US20070021624A1

  公开（公告）日：2007-01-25

  A method of inhibiting steroid sulphatase activity in a subject in need of same is described. The method comprises administering to said subject a steroid sulphatase inhibiting amount of a ring system compound; which ring system compound comprises a ring to which is attached a sulphamate group of the formula wherein each of R 1 and R 2 is independently selected from H, alkyl, alkenyl, cycloalkyl and aryl, or together represent alkylene optionally containing one or more hetero atoms or groups in the alkylene chain; and wherein said compound is an inhibitor of an enzyme having steroid sulphatase activity (E.C.3.1.6.2); and if the sulphamate group of said compound is replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at a pH 7.4 and 37° C. it would provide a K m value of less than 50 μM.